AbbVie (ABBV) Price Target Raised to $120.00 at Jefferies Group

AbbVie (NYSE:ABBV) had its price target raised by Jefferies Group from $115.00 to $120.00 in a report released on Thursday. Jefferies Group currently has a buy rating on the stock. Jefferies Group also issued estimates for AbbVie’s FY2018 earnings at $6.58 EPS, FY2019 earnings at $8.18 EPS, FY2020 earnings at $9.29 EPS, FY2021 earnings at $10.40 EPS and FY2022 earnings at $11.94 EPS.

A number of other brokerages have also issued reports on ABBV. BidaskClub raised AbbVie from a buy rating to a strong-buy rating in a research note on Wednesday, September 6th. Evercore ISI reaffirmed an outperform rating and issued a $100.00 price target (up from $95.00) on shares of AbbVie in a research note on Saturday, September 30th. Societe Generale lifted their price target on AbbVie in a research note on Tuesday, November 21st. Barclays reaffirmed a hold rating and issued a $68.00 price target on shares of AbbVie in a research note on Thursday, September 28th. Finally, ValuEngine lowered AbbVie from a strong-buy rating to a buy rating in a research note on Friday, December 1st. Seven equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $100.94.

Shares of AbbVie (NYSE:ABBV) traded up $1.05 on Thursday, reaching $100.43. The company’s stock had a trading volume of 2,218,921 shares, compared to its average volume of 4,280,800. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45. AbbVie has a one year low of $59.27 and a one year high of $100.12. The firm has a market capitalization of $160,080.00, a price-to-earnings ratio of 24.38, a P/E/G ratio of 1.18 and a beta of 1.53.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. During the same period last year, the company earned $1.21 earnings per share. AbbVie’s quarterly revenue was up 8.8% compared to the same quarter last year. analysts anticipate that AbbVie will post 5.55 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $2.84 dividend on an annualized basis and a yield of 2.83%. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s payout ratio is 62.14%.

In other AbbVie news, insider Henry O. Gosebruch sold 18,300 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the transaction, the insider now owns 81,287 shares of the company’s stock, valued at $7,360,537.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Timothy J. Richmond sold 87,040 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total value of $8,569,088.00. Following the transaction, the senior vice president now directly owns 113,118 shares in the company, valued at approximately $11,136,467.10. The disclosure for this sale can be found here. Insiders have sold 494,676 shares of company stock worth $47,237,938 in the last three months. 0.23% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acropolis Investment Management LLC purchased a new stake in AbbVie in the second quarter valued at $106,000. Hudock Capital Group LLC raised its position in AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after purchasing an additional 806 shares during the period. Ffcm LLC raised its position in AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after purchasing an additional 963 shares during the period. Bristlecone Advisors LLC purchased a new stake in AbbVie in the third quarter valued at $113,000. Finally, BDO Wealth Advisors LLC purchased a new stake in AbbVie in the second quarter valued at $115,000. 69.18% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “AbbVie (ABBV) Price Target Raised to $120.00 at Jefferies Group” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://transcriptdaily.com/2018/01/05/abbvie-abbv-price-target-raised-to-120-00-at-jefferies-group.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply